If approved, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind currently on the U.S. market after Leqembi from Biogen and Eisai.
An advisory committee to the Food and Drug Administration found the drug was safe and effective at slowing the progression of the disease, setting the stage for the agency to approve it.
Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2023 Earnings Call Transcript insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.
Novavax stock jumps on Sanofi Covid vaccine deal cnbc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cnbc.com Daily Mail and Mail on Sunday newspapers.